Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies by Petra Seidel et al.
Seidel et al. Respiratory Research 2012, 13:90
http://respiratory-research.com/content/13/1/90RESEARCH Open AccessThiazolidinediones inhibit airway smooth muscle
release of the chemokine CXCL10: in vitro
comparison with current asthma therapies
Petra Seidel1†, Hatem Alkhouri1†, Daniel J Lalor1, Janette K Burgess2,3, Carol L Armour1,4 and J Margaret Hughes1*Abstract
Background: Activated mast cells are present within airway smooth muscle (ASM) bundles in eosinophilic asthma.
ASM production of the chemokine CXCL10 plays a role in their recruitment. Thus the effects of glucocorticoids
(fluticasone, budesonide), long-acting β2-agonists (salmeterol, formoterol) and thiazolidinediones (ciglitazone,
rosiglitazone) on CXCL10 production by ASM cells (ASMC) from people with and without asthma were investigated
in vitro.
Methods: Confluent serum-deprived cells were treated with the agents before and during cytokine stimulation for
0-24 h. CXCL10 protein/mRNA, IκB-α levels and p65 activity were measured using ELISA, RT PCR, immunoblotting
and p65 activity assays respectively. Data were analysed using ANOVA followed by Fisher’s post-hoc test.
Results: Fluticasone and/or salmeterol at 1 and 100 nM inhibited CXCL10 release induced by IL-1β and TNF-α, but
not IFNγ or all three cytokines (cytomix). The latter was also not affected by budesonide and formoterol. In
asthmatic ASMC low salmeterol, but not formoterol, concentrations increased cytomix-induced CXCL10 release and
at 0.01 nM enhanced NF-κB activity. Salmeterol 0.1nM together with fluticasone 0.1 and 10 nM still increased
CXCL10 release. The thiazolidinediones ciglitazone and rosiglitazone (at 25 and 100 μM) inhibited cytomix-induced
CXCL10 release but these inhibitory effects were not prevented by the PPAR-g antagonist GW9662. Ciglitazone did
not affect early NF-κB activity and CXCL10 mRNA production.
Conclusions: Thus the thiazolidinediones inhibited asthmatic ASMC CXCL10 release under conditions when
common asthma therapies were ineffective or enhanced it. They may provide an alternative strategy to reduce
mast cell-ASM interactions and restore normal airway physiology in asthma.
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RosiglitazoneBackground
Asthma is a disease of the airways characterized by air-
way obstruction and airway hyperresponsiveness. The
airways of people with asthma are inflamed and undergo
continuous remodelling resulting in thicker airway walls
leading to airflow limitation [1]. The interaction between
airway smooth muscle cells (ASMC) and activated mast
cells may be crucial in the pathogenesis of asthma [2].
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reproduction in any medium, provided the orsmooth muscle (ASM) layer of asthmatic patients when
compared with non-asthmatic patients and the increase
in activated mast cell numbers in asthmatic ASM corre-
lates with the degree of airway hyper-responsiveness
[3,4].
The question of how mast cells accumulate in the
ASM is an area of active research. A variety of ASMC-
derived chemotactic and survival factors for mast cells
have been identified, including transforming growth fac-
tor (TGF)-β, CX3CL1 (fractalkine), stem cell factor and
CXCL10 (interferon inducible protein of 10 kDa (IP-10))
[5-8]. Previously we reported that ASMC induce human
lung mast cell migration via CXCR3 activation on thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chemokine receptor on mast cells found within the
ASM bundle and CXCL10, a potent mast cell chemo-
attractant and CXCR3 receptor ligand, is released from
ASMC. Most importantly, ASM in biopsies from asth-
matics express CXCL10 more often than controls [8]
and it is produced faster by asthmatic compared with
non-asthmatic ASMC in vitro [9]. Our previous findings
are consistent with CXCL10 playing an important role
in mast cell accumulation in the ASM. Thus how ASM
CXCL10 production can be inhibited most effectively is
of considerable interest.
To date the combination of inhaled glucocorticoids
(GC) and long-acting β-2 agonists (LABA) remains the
most effective treatment for asthma. Researchers have
shown in numerous in vitro studies that GC alone and
in combination with LABA reduce pro-inflammatory
cytokine secretion from non-asthmatic ASMC, including
the chemokines CXCL8 (IL-8) [10], CCL11 (eotaxin)
[11] and CCL5 (RANTES) [12]. However other chemo-
kines, particularly those induced by interferon(IFN)γ, are
resistant [13] and there are some asthma patients where
GC therapy is insufficient to control asthma symptoms
[14]. Therefore, it has been proposed that the addition
of other anti-inflammatory drugs such as peroxisome
proliferator-activated receptor (PPAR)γ agonists could
help to control asthma in difficult to treat patients [15].
PPARγ agonists such as the thiazolidinediones are cur-
rently licensed for the treatment of diabetes mellitus and
are thought to exert their effects mainly through activa-
tion of the PPARγ receptor. ASM PPARγ expression is
increased in bronchial biopsies from people with asthma
[16] and thiazolidinediones reduce airway hyperrepon-
siveness in animal models of allergic airways disease
[17,18]. However, there is evidence that PPARγ agonists
can also modulate the function of other pro-
inflammatory transcription factors such as nuclear factor
(NF)-κB [19,20]. Anti-inflammatory effects of PPARγ
agonists have been described in vivo in animal models
[17,21,22], as well as in vitro on ASMC [15,23]. It has
been hypothesized that adding this group of drugs could
therefore be beneficial in the therapy of asthma, particu-
larly when there is not an adequate response to current
asthma medications [15].
The aims of this study were to investigate the individ-
ual and combined effects of the GC fluticasone with the
LABA salmeterol or the thiazolidinedione ciglitazone, on
cytokine-induced CXCL10 release by ASMC from
people with and without asthma.
Methods
Materials
Salmeterol and fluticasone propionate (Glaxo Wellcome
R&D, Hertfordshire, UK and Sigma-Aldrich, Australia),budesonide and formoterol (AstraZeneca R&D, Lund,
Sweden) were freshly prepared in dimethyl sulfoxide
(DMSO) prior to use. Stocks of other agents were also
prepared in DMSO and aliquots stored at −20°C. The
thiazolidinediones ciglitazone (Sigma-Aldrich, Australia)
and rosiglitazone (kind gift of Professor David Hibbs)
and the β2-adrenoceptor antagonist butoxamine (Sigma-
Aldrich, Australia) were prepared as 10 mM stocks. The
irreversible PPARγ antagonist GW-9662 (Cayman, MI,
USA) was prepared as a 100 mM stock in DMSO. Re-
combinant human interleukin(IL)-1β, tumour necrosis
factor(TNF)-α (R&D Systems, Minneapolis, MN, USA)
and recombinant human IFNγ (BD Biosciences) were
reconstituted in sterile PBS containing 0.1% bovine
serum albumin (BSA) at 10 μg/ml and aliquots stored at
−20°C and −80°C respectively. All agents were diluted to
the appropriate working concentration in the medium
used to serum-deprive the cells.
Airway smooth muscle cell culture
Samples of resected lung and bronchial biopsies were
obtained and used with the ethical approval of the Syd-
ney South West Area Health Service and the Australian
Red Cross. Approval for this study was provided by the
Human Ethics Committee of The University of Sydney.
The people without asthma had a mean age of 59 ± 15.3
(SD) years (n=21), whereas those with asthma had a
mean age of 33.5 ± 13.6 years (n=18) and a positive bron-
chial challenge to mannitol [24] or methacholine [25]
and symptoms in the last 12 months.
Smooth-muscle bundles were dissected from the bron-
chial tissue and grown as explants as described previ-
ously [8,26] in DMEM supplemented with 10% FBS,
100 units/mL penicillin G, 100 μg/mL streptomycin
sulphate, 25 μg/mL amphotericin B, 4 mM L-glutamine
and 20 mM of HEPES growth medium pH 7.4, in a hu-
midified 5% carbon dioxide in air atmosphere at 37°C.
ASMC were identified by their morphology, positive
immunohistochemical staining for α-smooth muscle
actin and calponin and their typical ASMC “hill and val-
ley” pattern of growth. From passages 4–7 the cells were
harvested with trypsin-EDTA, washed and plated at a
density of 1 × 104 cells/cm2 in growth medium for all
experiments, except where nuclear extracts were gener-
ated, when cells were plated at a density of 2.5 × 104
cells/cm2. Before and at the end of any treatment period
the morphology and viability of the plated cells were
checked using phase contrast microscopy.
Drug treatment, cell stimulation and CXCL10 production
The effects of GC and LABA on cytokine induced
CXCL10 release were determined on ASMC from asth-
matic and non-asthmatic donors. The cells were grown
for a week and then serum starved using DMEM
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20 mM HEPES (pH 7.4) and 0.1% BSA. After 48 h,
ASMC were treated with salmeterol (0.1-100 nM) and/
or fluticasone (0.1-100 nM) or budesonide (0.1-100 nM)
and/or formoterol (0.1-100 nM) for 1 h prior to and
during stimulation with either IL-1β, TNF-α and IFNγ
alone, or in combination (cytomix), at a final cytokine
concentration of 10 ng/ml each. In studies to determine
β2-adrenoceptor involvement, asthmatic ASMC were
treated with the selective β2-adrenoceptor antagonist
butoxamine at a final concentration of 30 μM [27] 1 h
prior to and during the salmeterol treatment and cyto-
mix stimulation of the cells.
To investigate the effects of the thiazolidinediones,
ciglitazone and rosiglitazone, on cytokine induced
CXCL10 release, ASMC were treated with either agent
at 25 μM or 100 μM [28] for 0.5 h before and during
cytokine stimulation of the cells as above. The PPARγ
antagonist GW-9662 (10 μM) [29] was also added to
specified wells 0.5 h prior to treating the cells with cigli-
tazone or rosiglitazone. To determine whether flutica-
sone (0.1-100 nM) or salmeterol (0.1-100 nM) in
combination with ciglitazone (25 μM or 100 μM) caused
additional effects, asthmatic and non-asthmatic ASMC
were treated with both drugs 1 h prior to cytomix stimu-
lation as described above. All experiments had untreated
and vehicle controls. After a further 24 h incubation the
culture medium from each well (supernatant) was col-
lected, stored at −20°C and later analysed using CXCL10
Duo-set ELISA kits (R&D Systems) according to the
manufacturer’s instructions.
The effects of ciglitazone on ASMC CXCL10 mRNA
levels induced during 3 h stimulation with cytomix
were also determined as described previously [9]. Total
RNA was extracted from cell lysates using a NucleoS-
pin RNA 11 kit and protocol (Macherey-Nagel GmbH
& Co, Duren Germany). Reverse transcription of 1 μg
of extracted RNA was performed using the RevertAid
First Strand cDNA Synthesis Kit and protocol for the
use of random hexamer primers (Fermentas Life
Sciences, Hanover, MD). The resulting cDNA (2 μl)
was amplified using standard conditions and the
CXCL10 primer sets (Hs00171042_m1) multiplexed
with the eukaryotic 18S rRNA endogenous control
probe (Applied Biosystems, Melbourne Australia).
Results for CXCL10 were normalized against those for
18S and finally expressed as fold change over the ve-
hicle control.
NF-κB p65 DNA binding activity
To investigate the effects of salmeterol (0.001-0.01 nM)
and ciglitazone (25 μM or 100 μM) on NF-κB p65 tran-
scription factor DNA binding activity, ASMC from asth-
matic and non-asthmatic donors were treated with thedrugs and then stimulated with cytomix as before for 15
and 30 min. Nuclear extracts were generated using a
NE-PER nuclear and cytoplasmic extraction kit (Pierce
Biotechnology, Rockford, IL, USA) and nuclear NF-κB
p65 DNA binding activities measured using NF-kappa B
(p65) transcription factor activity assays (Cayman, Ann
Arbor, MI, USA) according to the manufacturers’
protocols.
IκB-α degradation
Total cell extracts were generated from ASMC treated
as described above, to examine IκB-α degradation. After
SDS-PAGE of these extracts, membranes were incubated
with the primary antibodies anti-IκBα (C21, 1:1000) and
anti-α-tubulin (DM1A, 1:1000, both Santa Cruz Biotech-
nology, Santa Cruz, CA). The primary antibodies were
then detected using horseradish peroxidase-conjugated
IgG antibodies (1:2000, anti-rabbit IgG or anti-mouse
IgG, both Cell Signaling Technology, Beverly, MA) and
visualized using enhanced chemiluminescence (PerkinEl-
mer, Wellesley, MA).
Data analysis
CXCL10 concentrations (pg/ml, ELISA) or optical dens-
ities (nm, NF-κB activity assay) from replicate treat-
ments were averaged and standardized to the specified
controls. The mean ± SEM was then calculated for the
ASMC from donors with or without asthma. Statistical
analyses were performed on all data using Statview and
significance (p<0.05) was determined by 1- or 2-way
ANOVA followed by a Fisher post-hoc test.
Results
GC and LABA modulation of cytokine-induced CXCL10
release
The effect of current asthma therapies on cytokine-
induced CXCL10 release were stimulus specific. IL-1β-
or TNF-α-induced CXCL10 production by asthmatic
(2145 ± 691 and 13928 ± 4773 pg/ml respectively) and
non-asthmatic (1565 ± 255 and 9043 ± 4140 pg/ml re-
spectively) ASMC after 24 h of stimulation was signifi-
cantly inhibited by salmeterol (1 and 100 nM) and
fluticasone (1 and 100 nM). CXCL10 levels were similar
to basal release (501 ± 254 and 406 ± 214 pg/ml respect-
ively) when the drugs were used in combination (Figure
1A and B). However the drugs, individually or in com-
bination, failed to inhibit IFNγ-induced CXCL10 release
by both asthmatic (15216 ± 5475 pg/ml) and non-
asthmatic (6354 ± 2252 pg/ml) ASMC (Figure 1C).
Individually (Figure 2A,B) or in combination
(Figure 2C), did not inhibit cytomix-induced CXCL10
release from either asthmatic (65764 ± 9578 pg/ml) or
non-asthmatic (51800 ± 6006 pg/ml) ASMC. Unexpect-
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Figure 1 The effects of fluticasone (Flutic) and salmeterol (Sal) on cytokine-induced CXCL10 release by asthmatic (A) and
non-asthmatic (NA) ASMC. Confluent serum-deprived ASMC were treated with fluticasone and/or salmeterol for 1 h prior to and during stimulation
with the cytokines (each at 10 ng/ml) A) IL-1β, B) TNF-α or C) IFNγ and CXCL10 release after 24 h quantified by ELISA. Bars, mean ± SEM.
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163 ± 40% (p<0.05, n=6, Figure 2B) from asthmatic
ASMC only. In addition, the lowest concentration of sal-
meterol (0.1 nM) in combination with fluticasone (0.1
and 10 nM) significantly increased cytomix-induced
CXCL10 release from asthmatic but not from non-asth-
matic, ASMC to 151 ± 39% and 180 ± 11% respectively
(Figure 2C).
The effects of formoterol (0.1, 1, 10 and 100 nM) and
budesonide (0.1, 1, 10 and 100 nM), by themselves or in
combination, were also investigated in parallel with sal-
meterol and fluticasone in three of the same experi-
ments and ASMC lines. In contrast to the salmeterol
findings above, there were no significant changes in
cytomix-induced CXCL10 production from either asth-
matic or non-asthmatic ASMC with these agents
(Figure 3A-C).β2-adrenoceptor involvement in the effects of salmeterol
When lower concentrations of salmeterol, 0.01 and
0.001 nM, were used they also significantly increased
cytomix-induced CXCL10 production by asthmatic
ASMC to 118 ±4% and 127 ± 11% respectively (p<0.05,
n=4, Figure 4A). Pre-treating the cells with the selective
β2-adrenoceptor antagonist butoxamine (30 μM) did not
reverse the salmeterol induced increases in CXCL10 re-
lease by the asthmatic cells (Figure 4A).
NF-κB involvement in the effects of salmeterol
As the transcription factor NF-κB is involved in ASMC
CXCL10 production, the effects of low salmeterol con-
centrations on the NF-κB pathway in asthmatic ASMC
were investigated. IκB-α remained fully degraded in the
presence of salmeterol at the concentrations indicated
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Figure 2 The effects of fluticasone and salmeterol on asthmatic (A) and non-asthmatic (NA) ASMC CXCL10 release induced by cytomix.
Confluent serum-deprived ASMC were treated with A) fluticasone, B) salmeterol or C) both agents for 1 h prior to and during stimulation with
cytomix (IL-1β, TNF-α and IFNγ combined, each at 10 ng/ml) and CXCL10 release after 24 h quantified by ELISA. Bars, mean ± SEM.
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salmeterol, 0.01 nM but not 0.001 nM, significantly
increased NF-κB p65 DNA binding activity by more
than 20% (p<0.05, n=4, Figure 4C).
None of the above treatments affected the viability of
the ASMC.
The effects of the thiazolidinediones on cytokine induced
CXCL10 release
Ciglitazone (25 and 100 μM) significantly reduced asth-
matic and non-asthmatic ASMC CXCL10 release
induced by the individual cytokines or cytomix
(Figure 5A and B). However, it was less effective against
IFNγ- or cytomix-induced CXCL10 release than IL-1β-
or TNF-α-induced release. The PPARγ antagonist GW-9662 (10 μM) did not prevent the inhibitory effects of
ciglitazone 25 and 100 μM on cytomix-induced CXCL10
release from either asthmatic or non-asthmatic ASMC
(Figure 5B).
Rosiglitazone also significantly reduced cytomix-
induced CXCL10 release by ASMC from one asthmatic
and two non-asthmatic donors. As for ciglitazone, the
PPARγ antagonist GW-9662 did not prevent the inhibi-
tory effects of rosiglitazone on CXCL10 release
(Figure 5C).
The effects of ciglitazone on the activation of NF-κB and
CXCL10 gene expression
As PPARγ agonists can negatively interfere with the
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Figure 3 The effects of budesonide and formoterol on asthmatic (A) and non-asthmatic (NA) ASMC CXCL10 release induced by
cytomix. Confluent serum-deprived ASMC were treated with A) budesonide, B) formoterol or C) both agents for 1 h prior to and during
stimulation with cytomix (IL-1β, TNF-α and IFNγ combined, each at 10 ng/ml) and CXCL10 release after 24 h quantified by ELISA. Bars, mean ±
SEM.
Seidel et al. Respiratory Research 2012, 13:90 Page 6 of 13
http://respiratory-research.com/content/13/1/90ciglitazone, with and without the antagonist GW-9662,
on IκB-α degradation and NF-κB p65 activity were
investigated. None of the ciglitazone concentrations used
had an effect on IκB-α degradation or NF-κB activity,
detected in whole cell lysates or nuclear extracts respect-
ively, in the first 0.5 h after cytomix stimulation of the
asthmatic and non-asthmatic ASMC (Figure 6A and B).
Given early signalling events leading to NF-κB-
mediated gene transcription were not affected, we then
determined the effect of ciglitazone on CXCL10 mRNA
levels. Ciglitazone had no significant effects on CXCL10
mRNA levels in the asthmatic and non-asthmatic ASMC
following 3 h cytomix stimulation (Figure 6C).
The effects of asthma therapies in combination with
ciglitazone
In view of the inhibitory effects of ciglitazone on
CXCL10 protein release, but not mRNA production,
whether or not it was more effective when combinedwith fluticasone or salmeterol was also investigated. In
non-asthmatic ASMC fluticasone 0.1-100 nM signifi-
cantly reduced the inhibitory effects of 25 μM, but not
100 μM, ciglitazone on cytomix-induced CXCL10 re-
lease (Figure 7), whereas it had no significant effects in
asthmatic ASMC. Salmeterol 0.1-100 nM caused no sig-
nificant changes to any of the inhibitory effects of cigli-
tazone (data not shown).
None of the above treatments affected the viability of
the ASMC.
Discussion
In this study the inflammatory conditions under which
current asthma therapies down-regulate production of
the mast cell chemoattractant CXCL10 by ASMC from
people with and without asthma were established. The
GC fluticasone and LABA salmeterol very effectively
inhibited CXCL10 release induced by TNF-α or IL-1β,
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Figure 4 β2-adrenoceptors and NF-κB involvement in the effects of salmeterol on asthmatic (A) ASMC. The effects of lower salmeterol
concentrations on A) CXCL10 release in the presence or absence of the selective β2-adrenoceptor antagonist butoxamine 30 μM or its vehicle, or
B) IκB-α degradation (a representative immunoblot from 1 of 4 different ASMC examined) and C) NF-κB p65 DNA binding activity by confluent
serum-deprived cells stimulated with cytomix for 24 h (A), or up to 30 min (B and C), were determined. Butoxamine was added to the cells 1 h
before salmeterol. US, unstimulated; cyt, cytomix.
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lease. Surprisingly, salmeterol at sub-nanomolar concen-
trations increased CXCL10 release induced by all three
cytokines together (cytomix). This effect of salmeterol
was most likely mediated by increased NF-κB activity,
but does not appear to be a class effect, as low formo-
terol concentrations did not affect release. In addition,
fluticasone did not prevent the salmeterol-induced
CXCL10 increase. Importantly, the thiazolidinediones
ciglitazone and rosiglitazone were effective inhibitors of
cytokine-induced CXCL10 release. However, their action
appeared to be independent of PPARγ and NF-κB p65activity. Nevertheless thiazolidinediones may provide an
alternative therapeutic strategy for GC and LABA resist-
ant asthma.
TNF-α- or IL-1β-induced CXCL10 release by ASMC
from people with and without asthma was strongly
inhibited by GC and LABA treatment in this study. This
is in agreement with previous studies in which flutica-
sone or salmeterol inhibited release of other asthma-
relevant chemokines induced by TNF-α [10-12]. In
addition, Clarke et al. [13] showed fluticasone had an
inhibitory effect on TNF-α-induced CXCL10 release in
non-asthmatic ASMC. Similarly, IL-1β induced
RTZ 25 µM       RTZ 100 µM
B
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Figure 5 The effects of ciglitazone (CTZ) and rosiglitazone (RTZ) on cytokine-induced CXCL10 release by asthmatic (A) and non-
asthmatic (NA) ASMC. Confluent serum-deprived ASMC were treated with vehicle or A) ciglitazone for 0.5 h and then stimulated with the
cytokines (10 ng/ml each) IL-1β, TNF-α or IFNγ, or B) and C) the PPARγ antagonist GW9662 for 0.5 h prior to and during treatment with B)
ciglitazone or C) rosiglitazone for 0.5 h followed by stimulation with cytomix (IL-1β, TNF-α and IFNγ combined, each at 10 ng/ml). CXCL10 release
after 24 h cytokine stimulation was quantified.
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strongly inhibited by fluticasone, salmeterol or both
combined [30]. Nie et al. [15] used ChIP analysis to
demonstrate that the effects of fluticasone and salme-
terol on ASMC TNF-α-induced eotaxin were mediated
by inhibition of NF-κB p65 DNA binding to the
eotaxin promoter. A similar mode of action could be
assumed for TNF-α-induced CXCL10, as NF-κB also
plays an important role in TNF-α-induced CXCL10 in
ASMC [31].
In this study neither CXCL10 induced by IFNγ, nor
CXCL10 induced by IFNγ combined with TNF-α andIL-1β (cytomix), were reduced when asthmatic and non-
asthmatic ASMC were treated with GC or LABA indi-
vidually, or in combination. In contrast, salmeterol has
previously been reported to inhibit IFNγ–induced
CXCL10 production by an airway epithelial cell line [32].
However, similar to this study, others observed the in-
hibitory effects of fluticasone on TNF-α-induced
CXCL10 disappeared when non-asthmatic ASMC were
stimulated with a combination of TNF-α and IFNγ
[13,33]. Stimulation with TNF-α and IFNγ together
inhibits ASMC glucocorticoid receptor (GR)α DNA
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Figure 6 The effects of ciglitazone on NF-κB activation and CXCL10 gene transcription. Confluent serum-deprived asthmatic (A) and
non-asthmatic (NA) ASMC were treated with the PPARγ antagonist GW-9662 and/or ciglitazone prior to and during stimulation with cytomix and
A) IκB-α degradation, B) NF-κB p65 DNA binding activity and C) CXCL10 mRNA levels determined at 15 and 30 min (A and B) or 3 h using
RT-PCR (C) respectively.
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have clinical relevance because CXCL10 production in
the airway mucosa of people with asthma is increased by
oral corticosteroids [36].
Subnanomolar concentrations of salmeterol further
up-regulated cytomix-induced CXCL10 secretion in
asthmatic ASMC, whereas formoterol did not. Formo-
terol was used at the same concentrations on the same
ASMC in parallel with salmeterol in the experiments
and did not cause any changes in CXCL10 levels. Thus
this effect of salmeterol was not a drug class effect, or
due to differences in lung donor age. A difference in
effects of the two LABA is perhaps not unexpected as
these agents differ markedly in their agonist properties.
Salmeterol does not associate with the β2-adrenoceptor
preferentially as formoterol does. Instead it partitions to
the outer lipid bilayer of cells where it is retained. Twomodels have been proposed for salmeterol receptor en-
gagement: 1) it is anchored to an exosite and engages
and disengages from the receptor, or 2) it diffuses
through the bilayer to engage the receptor through the
side [37,38]. In support of the latter, it has lower efficacy
and onset of action than formoterol and increases mem-
brane fluidity, which may affect receptor function and
decrease its own efficacy reviewed in [39]. There is ex-
tensive evidence from the development of salmeterol
that β2-adrenoceptor antagonists inhibit all its effects
[40]. Given the reported efficacy of the β2-adrenoceptor
antagonist butoxamine [27], its lack of effect on the
salmeterol-induced increase in asthmatic ASMC CXCL10
release was unexpected. It is consistent with the effect of sal-
meterol not beingmediated through classic β2-adrenoceptor
engagement and signalling. However it does not eliminate
the involvement of exosite binding or diffusion from the


























25 100Veh 0.1     1    10   1000.1    1     10   100 0.1    1    10   100
*
NA n=5





















p < 0.05 vs vehicle
#
Figure 7 The effects of ciglitazone and fluticasone on asthmatic (A) and non-asthmatic (NA) ASMC CXCL10 release induced by cytomix.
Confluent serum-deprived ASMC were treated with ciglitazone and fluticasone or vehicle 1 h prior to and during stimulation with cytomix and
CXCL10 release after 24 h quantified using ELISA.
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same receptor binding sites [37,41]. It may be possible
for salmeterol to bind to the exosite/receptor sites not
blocked by butoxamine and activate signalling leading to
the increase in CXCL10 production. Salmeterol ≥ 1pM
increased IL-6 and CXCL8 production by the lung
epithelial cell line BEAS-2B stimulated with IL-1β and
histamine. The β2-adrenoceptor antagonist ICI 118551
blocked the effects of 100nM salmeterol, confirming β2-
adrenoceptor involvement at that high concentration, but
it was not tested against subnanomolar concentrations
[42] similar to those used in this study.
NF-κB plays an important role in cytokine induced
CXCL10 production. In intestinal epithelial cells, IL-1β
and IFNγ alone, and in combination, up-regulated
CXCL10 in an NF-κB dependent manner [43]. In ASMC
from people with chronic obstructive pulmonary disease
(COPD), TNF-α induced CXCL10 via NF-κB activation,
whereas IFNγ only induced a weak activation of NF-κB
[31] and activated STAT-1 as well, but not AP-1 [13].
Stimulation with these cytokines together results in syn-
ergistic increases in CXCL10 production by ASMC
[9,13]. In this study, we showed in the asthmatic ASMC
that cytomix stimulation strongly induced NF-κB p65
DNA binding activity and treatment with very low sal-
meterol concentrations further enhanced it. This
increased p65 DNA binding activity may contribute to
the increases in cytomix-induced CXCL10 and is con-
sistent with the hypothesis that salmeterol increases
asthmatic ASMC cytomix-induced CXCL10 production
in an NF-κB dependent manner. However further stud-
ies are needed to establish whether or not the increase
in p65 DNA binding activity is specific to asthmaticASMC, occurs in the CXCL10 promoter and over what
salmeterol concentration range this occurs.
The salmeterol enhancement of cytomix-induced
CXCL10 release was specific to asthmatic ASMC.
Whereas the salmeterol-induced increases in IL-6 and
CXCL8 secretion by BEAS-2B cells were GC sensitive
[42], the salmeterol enhancement of asthmatic ASMC
CXCL10 production reported here was not. In ASMC
from people with asthma there is increasing evidence of
reduced sensitivity to steroids and intrinsic changes in
intracellular signalling. These include altered calcium
homeostasis and increased mitochondrial biogenesis
[44,45]. Cytomix-induced NFκB transcriptional activity
may be increased in the presence of salmeterol as a re-
sult because ASMC NFκB transcriptional activity is sen-
sitive to changes in calcium [46]. As well, asthmatic
ASMC β2-agonist–induced cAMP levels are lower due
to increased PDE4 levels and activity [47] and cytomix-
induced MAPK signalling is altered [9]. Production of
cAMP activates cAMP-dependent protein kinase (PKA)
and exchange protein directly activated by cAMP (Epac).
Whether PKA and/or Epac expression or activity is
altered in asthmatic ASMC warrants investigation. Not-
ably, β2-agonists regulate non-asthmatic ASMC func-
tions via Epac [48,49] and β2-agonist enhancement of
bradykinin-induced CXCL8 release is mimicked by acti-
vation of either PKA or Epac and involves the MAPK
ERK [49]. We reported recently that the MAPK JNK,
but not p38 or ERK, is involved in CXCL10 production
following cytomix stimulation, but JNK activation is
markedly reduced in asthmatic compared to non-
asthmatic ASMC [9]. Thus the salmeterol-induced in-
crease in CXCL10 would seem less likely to be mediated
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pathway involved in receptor desensitization, leads to
increased inflammation again through ERK/p38 MAPK
activation reviewed in [50]. It may still be of interest
however, as β-arrestin-2 also interacts with PI3K and
some differences in expression of PI3K isoforms in asth-
matic and non-asthmatic ASMC have been reported
[51,52]. These scenarios are only likely if salmeterol does
stimulate some receptor-mediated signalling in the asth-
matic ASMC despite the presence of butoxamine.
Clearly multiple signalling pathways are potentially
involved and carefully controlled follow-up studies are
needed to investigate which contribute to the
salmeterol-induced increase in CXCL10 release by asth-
matic ASMC and the functional consequences of this
enhanced response.
The observed insensitivity of IFNγ- or cytomix-
induced CXCL10 to current asthma medications empha-
sizes the need for novel compounds that can inhibit
these nonresponsive pathways. In this respect thiazolidi-
nediones show some promise. They are anti-
inflammatory in animal models of asthma [20,21] and
have bronchodilatory effects in smokers with asthma
[53]. In vitro they do have anti-inflammatory and anti-
remodelling effects, but these can be cell- and stimulus-
specific and involve diverse and often complex mechan-
isms that are still being elucidated. Rosiglitazone, by
increasing PPARγ signalling, inhibits CXC3CL1 signal-
ling [54] and hypoxia-induced increases in lung TGF-b
signalling and collagen deposition [55], but both piogli-
tazone and rosiglitazone reduce orbital fibroblast hyalur-
onan synthesis and T-cell adhesion to the fibroblasts in
a PPAR-independent manner [56]. In ASMC they also
have PPARγ-dependent and independent effects to in-
hibit ASMC proliferation and secretion of some key pro-
inflammatory mediators including CCL11 (eotaxin),
CCL2 (MCP-1), CCL5 (RANTES) and IL-6 [15,18,23].
In this study the thiazolidinedione ciglitazone strongly
inhibited IFNγ- and cytomix-induced ASMC CXCL10
secretion. This appears to be a class effect as rosiglita-
zone, which is currently used to treat people with type II
diabetes mellitus, also inhibited cytomix-induced
CXCL10 release. Although Ward and colleagues [18]
found the anti-proliferative effects of rosiglitazone in
ASMC were sensitive to the PPARγ antagonist GW-
9662, in this study GW-9662 did not prevent ciglitazone/
rosiglitazone inhibition of asthmatic and non-asthmatic
ASMC CXCL10 production. Further, in contrast to
reports that PPARγ agonists can inhibit NF-κB activity
[20] and subsequent CXCL10 production [57] in other
cell types, there was no evidence that ASMC NF-κB ac-
tivity was inhibited by ciglitazone or that it affected early
CXCL10 gene transcription. In addition any reported
thiazolidinedione effects on JAK-STAT signalling [58] arenot applicable to inhibition of CXCL10 induced by IL-1β
or TNF-α Thus we propose ciglitazone inhibits asthmatic
and non-asthmatic ASMC CXCL10 release via a PPARγ-
independent post-transcriptional mechanism. Nie and
colleagues [15] have also provided evidence that PPARg
agonists can have post-transcriptional inhibitory effects
on ASMC chemokine production. They found the
PPARγ agonist 15d-PGJ2 and thiazolidinedione troglita-
zone inhibited TNF-α-induced CCL2 post-transcription-
ally, but prevented NFκB binding to the CCL11 gene
promoter and inhibited CCL11 gene transcription. Zhu
and colleagues [23] recently reported similar findings to
our study: rosiglitazone and/or troglitazone inhibition of
ASMC cytokine-induced IL-6 and CCL5 production was
not prevented by GW-9662, or PPARγ knockdown, and
was not accompanied by inhibition of NF-κB activation.
Although further studies elucidating the different
mechanisms of action of the thiazolidinediones are
needed, the strong inhibition of ASMC CXCL10 release
observed, irrespective of cytokine stimulus, is evidence
of another beneficial anti-inflammatory effect the thiazo-
lidinediones might have in asthma and other obstructive
respiratory diseases. However in contrast to the findings
of Nie and colleagues for CCL5 and CCL11 [15], in this
study there were no additional/synergistic inhibitory
effects on CXCL10 release when ciglitazone was used in
combination with fluticasone or salmeterol.
Conclusions
It is widely accepted that the accumulation of activated
mast cells within ASM bundles is important in the
pathogenesis of eosinophilic asthma and that ASMC
derived CXCL10 is involved in mast cell migration to
the ASM [8]. In this study evidence of how current
asthma therapies affect asthmatic ASMC CXCL10 re-
lease induced when different cytokines are present and
the first evidence that salmeterol may sometimes in-
crease CXCL10 release has been provided. As well, the
efficacy of the thiazolidinediones in reducing asthmatic
and non-asthmatic ASMC CXCL10 release has been
demonstrated, even under inflammatory conditions
where current asthma therapies were ineffective or
enhanced release. Currently approved thiazolidinediones
may be effective alternative treatments to reduce mast
cell-ASM interactions and restore normal airway physi-
ology in asthma.
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